Emerging biotechs and their investors are exploring partnerships with drug companies at much earlier stages. Experts at ...
Policy pressure, affordability gaps, and consumer expectations are reshaping how pharma companies think about direct to patient access, according to Deepak Thomas and Sari Kaganoff.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback